ReCode Therapeutics to Participate in Upcoming June Investor Conferences

·1 min read

MENLO PARK, Calif. & DALLAS, Jun 14, 2021--(BUSINESS WIRE)--ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its SORT-LNP™ platform for the treatment of life-limiting respiratory diseases, today announced that the Company will participate in two upcoming virtual investor conferences in June:

  • JMP Securities Life Sciences Conference
    Presentation by David Lockhart, Ph.D., CEO and President; Julie Eastland, COO and CFO, will also participate in virtual 1x1 meetings
    Date: Wednesday, June 16, 2021
    Time: 4:00 – 4:25 p.m. ET

    The presentation will be webcast live and available for replay here.

  • LifeSci Partners Genetic Medicines Summit
    Presentation and Q&A by David Lockhart, Ph.D., CEO and President
    Date: Tuesday, June 22, 2021
    Time: 1:00 – 1:25 p.m. ET

    An archived replay of the presentation will be made available on the Company’s website following the presentation.

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful, proprietary SORT-LNP™ platform to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its SORT-LNP™ and nucleic acid technologies, utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit and follow us on Twitter @ReCodeTx and LinkedIn.

View source version on


Media Contact:
Will Zasadny
Canale Communications, Inc.
(619) 961-8848

Investor Contact:
Sarah McCabe
Stern Investor Relations

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting